Review
Immunology
Bernd Heinrich, Firouzeh Korangy
Summary: Innate lymphoid cells (ILCs) are a heterogeneous population of the innate immune system that play a crucial role in maintaining immune homeostasis. They exhibit high plasticity, allowing them to quickly respond to changes in their microenvironment. ILCs can transdifferentiate into different subsets in the tumor microenvironment, influencing the immune response and tumor therapy. This review summarizes the functional and plastic heterogeneity of ILCs in homeostasis and disease, with a focus on tumor-driven plasticity and the impact of ILC-induced inflammation on the tumor microenvironment and anti-tumor immunity.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Immunology
Raghad Khaleafi, Jelena Zeleznjak, Sapir Cordela, Shani Drucker, Tihana Lenac Rovis, Stipan Jonjic, Yotam Bar-On
Summary: Reovirus infection can downregulate NKG2D ligands on tumor cells, impairing the recognition and elimination of tumors by natural killer (NK) cells. This finding may lead to the development of new reovirus-based therapeutics to enhance the anti-tumor immune response.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Cell Biology
Xiaoying Li, Yueyao Yang, Qian Huang, Yu Deng, Fukun Guo, Gang Wang, Ming Liu
Summary: ICIs have revolutionized cancer treatment, but finding robust biomarkers for individualized immunotherapy is crucial. Functional interaction between TME and immune cells may serve as a predictive biomarker for ICIs. Personalized strategies can enhance the effectiveness of ICIs.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Review
Cell Biology
Ryohichi Sugimura, Yiming Chao
Summary: The tumor microenvironment contains various innate immune cells that have important roles in regulating tumor progression. Accurate characterization of these cells at the single-cell level using single-cell technology can enhance the potential of cancer immunotherapy.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2022)
Review
Immunology
Prakash Sah, Lauren A. Zenewicz
Summary: Innate lymphoid cells (ILCs) play important roles in maintaining tissue homeostasis, regulating inflammation, and immune responses to infections. They respond quickly to environmental cues and are enriched at barrier surfaces, such as the gastrointestinal (GI) tract, where they are critical in eliminating pathogens. Pathogenic bacteria, however, can manipulate these immune responses to their advantage, affecting the host's immune defense and microbiota. This review discusses the recent progress in understanding the role of ILCs during enteric bacterial infections, the mechanisms by which pathogens modulate the immune response, and the implications for developing new therapies.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Neurosciences
Xu Guo, Rui Sui, Haozhe Piao
Summary: This review summarizes the role of exosomes released by glioma cells in the tumor microenvironment, including mediating intercellular communication, inducing macrophage polarization, and inhibiting immune cell activity. Exosomes play a crucial regulatory role in the development and immune evasion of glioma.
CNS NEUROSCIENCE & THERAPEUTICS
(2023)
Article
Oncology
Feifei Guo, Yi Zhang, Ling Bai, Jiuwei Cui
Summary: Cancer stem cells (CSCs) are a small group of cancer cells with stem cell-like properties, which can be used for identifying malignant tumor phenotypes and patients with poor prognosis. Targeting CSCs has been shown to improve the effectiveness of cancer therapies. However, CSCs are resistant to conventional treatment methods such as radiotherapy and chemotherapy, hence the need for more effective anti-CSC therapies.
Review
Immunology
Lu Chen, Yuchen Wang, Qingqing Hu, Yuxi Liu, Xuchen Qi, Zhihua Tang, Haihong Hu, Nengming Lin, Su Zeng, Lushan Yu
Summary: The tumor microenvironment (TME) plays a crucial role in tumor progression by impeding the immune response through altering the metabolic activity of immune cells. Transporter-mediated regulation of nutrient acquisition and metabolite efflux is important for the proliferation and physiological functions of both tumor and immune cells, as well as for modulating immune responses in the TME. This review summarizes the metabolic characteristics of the TME, discusses the effects of abundant metabolites on immune cell function and transporter expression, and examines the mechanism of tumor immune escape caused by transporter dysfunction. Additionally, transporter-targeted antitumor therapeutic strategies are introduced to provide new insights into the development of antitumor drugs and rational drug usage for clinical cancer therapy.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Oncology
Jianyun Jiang, Hongmei Ying
Summary: This paper reviews the mechanisms by which nasopharyngeal carcinoma cells evade immune surveillance and the methods attempted to restore immunity. Chronic Epstein-Barr virus infection is found to be the most common causative agent in nasopharyngeal carcinoma.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
(2022)
Review
Oncology
Yingqi Qiu, Tong Chen, Rong Hu, Ruiyi Zhu, Chujun Li, Yingchen Ruan, Xiaoling Xie, Yuhua Li
Summary: This review highlights the critical role of TAMs in tumor immune evasion, discussing their interactions with other immune cells and factors, and summarizing relevant studies to provide new insights for immunotherapy. Macrophage-targeted therapy is expected to be the next frontier in cancer immunotherapy.
BIOMARKER RESEARCH
(2021)
Article
Oncology
Katarina Pinjusic, Olivier Andreas Dubey, Olga Egorova, Sina Nassiri, Etienne Meylan, Julien Faget, Daniel Beat Constam
Summary: This study reveals that Activin-A secretion by melanoma cells inhibits adaptive antitumor immunity by indirectly inhibiting CD8(+) T cell infiltration, regardless of BRAF status. It is also found that Activin-A/INHBA expression is correlated with resistance to anti-PD1 therapy in melanoma patients and impairs response to combination anti-cytotoxic T-Lymphocyte associated protein 4/anti-PD1 treatment in preclinical models.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Review
Immunology
Chenglin Lu, Ying Liu, Nasra Mohamoud Ali, Bin Zhang, Xiaonan Cui
Summary: Innate immune cells in the tumor microenvironment determine the occurrence and development of tumors by secreting various factors. Understanding their role can improve therapeutic approaches and prognosis. This review provides an overview of the biology, role, and immunotherapy of innate immune cells, aiming to guide future research and clinical trials.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Cell Biology
Martina Mang Leng Lei, Terence Kin Wah Lee
Summary: Immune cells play a crucial role in driving cancer cells towards stemness and enabling cancer stem cells to evade immune surveillance by affecting various immune cells in the tumor microenvironment. Targeting CSCs with immunotherapy disrupts the interaction between immune cells and CSCs, offering a novel strategy against cancer.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Review
Biochemistry & Molecular Biology
Hochung Jang, Eun Hye Kim, Sung-Gil Chi, Sun Hwa Kim, Yoosoo Yang
Summary: This review focuses on utilizing nanoparticles to target innate immune cells in tumor microenvironments. It emphasizes the immune-suppressive properties of some innate immune cells that limit clinical benefits, and the potential development of strategies by understanding the cross-talk between tumors and innate immune cells.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Review
Immunology
Shirin Hekmatirad, Milad Moloudizargari, Marjan Fallah, Atena Rahimi, Vahdat Poortahmasebi, Mohammad Hossein Asghari
Summary: This review examines the modulatory effects of melatonin on various components of the tumor immune microenvironment. Melatonin can alter macrophage polarization and prevent M2 induction. It also inhibits the conversion of fibroblasts into cancer-associated fibroblasts and prevents cancer cell stemness. Furthermore, melatonin can impact the composition and secretion levels of tumor-derived exosomes, favoring a more effective anti-tumor immune response. Based on its effects on normal cells, tumor cells, and microenvironment components, melatonin could be a promising compound for combination with conventional immune-targeted therapies to enhance their efficacy.
IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY
(2023)
